Resource Type

Journal Article 313

Conference Videos 8

Year

2024 1

2023 27

2022 38

2021 27

2020 26

2019 23

2018 20

2017 21

2016 13

2015 19

2014 12

2013 11

2012 13

2011 7

2010 16

2009 13

2008 10

2007 11

2002 1

2000 2

open ︾

Keywords

molecular dynamics 9

targeted therapy 8

cancer therapy 7

cancer 6

immunotherapy 6

molecular dynamics simulation 6

therapy 6

gene therapy 5

drug resistance 4

hepatocellular carcinoma 4

China 3

Molecular dynamics simulation 3

molecular classification 3

molecular docking 3

molecular epidemiology 3

molecular markers 3

Alzheimer’s disease 2

COVID-19 2

Machine learning 2

open ︾

Search scope:

排序： Display mode:

Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis

Yue Yu, Jie He

Frontiers of Medicine 2013, Volume 7, Issue 2,   Pages 157-171 doi: 10.1007/s11684-013-0272-4

Abstract: Molecular biology techniques, particularly gene expression microarrays, proteomics, and next-generationsequencing, have recently been developed to facilitate effectively its molecular classification.The underlying etiology, pathogenesis, therapeutics, and prognosis of NSCLC based on an improved molecularThis review focuses on the molecular classification of NSCLC based on gene expression microarray technology

Keywords： non-small-cell lung cancer     molecular typing     individualized medicine     molecular-targeted therapy     gene expression    

HTML PDF Collect

Molecular classification and molecular targeted therapy of cancer

Miao Xu, Jianyong Shao, Yixin Zeng

Frontiers of Medicine 2013, Volume 7, Issue 2,   Pages 147-149 doi: 10.1007/s11684-013-0274-2

HTML PDF Collect

Molecular markers and pathogenically targeted therapy in non-small cell lung cancer

Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD

Frontiers of Medicine 2009, Volume 3, Issue 3,   Pages 245-255 doi: 10.1007/s11684-009-0044-3

Abstract: Over the last decade, molecular genetic abnormalities have been described in NSCLC, including chromosomalThese molecular markers in NSCLC demonstrated close associations with the development of lung cancertherapy, and prognosis in NSCLC.Recent clinical data have revealed that targeted therapy might be the second-line therapy as an alternativethat we can further identify effectiveness of targeted therapy in the future.

Keywords： lung cancer     carcinoma     non-small cell lung cancer     molecular markers     targeted therapy    

HTML PDF Collect

Molecular targeted therapy of gynecological malignant tumors: the development and challenge, from laboratory

Pengming SUN PhD, MD , Jalid SEHOULI PhD, MD , Lihui WEI BM ,

Frontiers of Medicine 2009, Volume 3, Issue 3,   Pages 256-264 doi: 10.1007/s11684-009-0052-3

Abstract: More and more molecular drugs based on targeted therapy have been utilized in the treatment of gynecologicIn this article, we systematically review the current targeted therapeutic trials running in clinic.Other planned or ongoing trials currentlytargeted at molecular markers which may play important rolesin gynecological carcinogenesis andprogression suggest that combination chemotherapy with moleculartargeted therapy will ultimately be an importantoption.

Keywords： target therapy     gynecologic malignant tumors     clinical trail     molecular medicine    

HTML PDF Collect

Synthesis and application of superparamagnetic iron oxide nanoparticles in targeted therapy and imaging

Liangqian Tong, Ming Zhao, Shu Zhu, Jing Chen

Frontiers of Medicine 2011, Volume 5, Issue 4,   Pages 379-387 doi: 10.1007/s11684-011-0162-6

Abstract: Superparamagnetic iron oxide (SPIO) nanoparticles have become a popular strategy of cancer treatment and molecularligand-conjugated, and/or drug-loaded SPIO nanoparticles, as powerful tools for targeted imaging andtherapy.Moreover, the applications of SPIO nanoparticles that integrate diagnosis and therapy in SPIO nanoparticlestherapy, and cancer imaging.

Keywords： nanoparticles     superparamagnetic iron oxide     targeted therapy     molecular imaging     cancer    

HTML PDF Collect

Precision medicine in acute lymphoblastic leukemia

Ching-Hon Pui

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 689-700 doi: 10.1007/s11684-020-0759-8

Abstract: Further improvement in outcome will need to rely more heavily on molecular therapeutic as well as immuno- and cellular-therapy approaches together with precise risk stratification.There are other fusions or mutations that may serve as putative targets, but effective targeted therapyWith the expanding therapeutic armamentarium, we should start focus on rational combinations of targetedtherapy with non-overlapping toxicities.

Keywords： acute lymphoblastic leukemia     molecular therapeutics     targeted therapy     tyrosine kinase inhibitors     immunotherapy     CAR T-cell therapy    

HTML PDF Collect

Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies

Peter B. Alexander,Xiao-Fan Wang

Frontiers of Medicine 2015, Volume 9, Issue 2,   Pages 134-138 doi: 10.1007/s11684-015-0396-9

Abstract:

Drug resistance is a major factor that limits the efficacy of targeted cancer therapies.mechanisms of resistance to receptor tyrosine kinase inhibitors, which are the most prevalent class of targeted

Keywords： targeted therapy     drug resistance     receptor tyrosine kinases     cancer    

HTML PDF Collect

mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?

Shi-Yong Sun

Frontiers of Medicine 2021, Volume 15, Issue 2,   Pages 221-231 doi: 10.1007/s11684-020-0812-7

Abstract: scientific rationale, the intriguing question is why cancers are insensitive or not responsive to mTOR-targetedcancer therapy in clinics.ERK, and Mnk/eIF4E survival signaling pathways that compromise the efficacy of rapalog-based cancer therapyThese new findings may also offer us the opportunity to rationally utilize mTOR inhibitors in cancer therapy

Keywords： mTOR     cancer therapy     resistance     GSK3     protein degradation     E3 ubiquitin ligase     PD-L1    

HTML PDF Collect

Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects

Zhen Wang, Jianhui Wu, Xiuyun Tian, Chunyi Hao

Frontiers of Medicine 2019, Volume 13, Issue 4,   Pages 427-437 doi: 10.1007/s11684-018-0672-6

Abstract: Tyrosine kinase and γ-secretase inhibitors are primarily used in the targeted therapy of DF.Previous studies that focused on the mechanism, efficacy, and safety of targeted therapy for DF wereThe efficacy and safety of targeted therapy were compared with those of other systemic therapy optionsTargeted therapy does not provide considerable advantages in efficacy and safety over other medical treatmentstherapy of DF.

Keywords： targeted therapy     desmoid-type fibromatosis     tyrosine kinase inhibitor     γ-secretase inhibitor    

HTML PDF Collect

Progress and challenges in RET-targeted cancer therapy

Frontiers of Medicine 2023, Volume 17, Issue 2,   Pages 207-219 doi: 10.1007/s11684-023-0985-y

Abstract: The rearranged during transfection (RET) is a receptor protein tyrosine kinase. Oncogenic RET fusions or mutations are found most often in non-small cell lung cancer (NSCLC) and in thyroid cancer, but also increasingly in various types of cancers at low rates. In the last few years, two potent and selective RET protein tyrosine kinase inhibitors (TKIs), pralsetinib (BLU-667) and selpercatinib (LOXO-292, LY3527723) were developed and received regulatory approval. Although pralsetinib and selpercatinib gave high overall response rates (ORRs), < 10% of patients achieved a complete response (CR). The RET TKI-tolerated residual tumors inevitably develop resistance by secondary target mutations, acquired alternative oncogenes, or MET amplification. RET G810 mutations located at the kinase solvent front site were identified as the major on-target mechanism of acquired resistance to both selpercatinib and pralsetinib. Several next-generation of RET TKIs capable of inhibiting the selpercatinib/pralsetinib-resistant RET mutants have progressed to clinical trials. However, it is likely that new TKI-adapted RET mutations will emerge to cause resistance to these next-generation of RET TKIs. Solving the problem requires a better understanding of the multiple mechanisms that support the RET TKI-tolerated persisters to identify a converging point of vulnerability to devise an effective co-treatment to eliminate the residual tumors.

Keywords： pralsetinib     selpercatinib     RET-alteration     lung cancer     thyroid cancer     tumor-agnostic therapy     drug    

HTML PDF Collect

Potential unreliability of ALK variant allele frequency in the efficacy prediction of targeted therapy

Frontiers of Medicine 2023, Volume 17, Issue 3,   Pages 493-502 doi: 10.1007/s11684-022-0946-x

Abstract: heterogeneity (ITH) has been proven to contribute to the poor treatment response and the resistance to targetedwhether the variant allele frequencies (VAFs) of ALK fusions can help assess ITH and predict targetedtherapy efficacy.ALK VAF determined by hybrid capture-based NGS is probably unreliable for ITH assessment and targetedtherapy efficacy prediction in NSCLC.

Keywords： situ hybridization     immunohistochemistry     variant allele frequency     intratumoral heterogeneity     targetedtherapy    

HTML PDF Collect

A small-molecule pan-HER inhibitor alone or in combination with cisplatin exerts efficacy against nasopharyngeal carcinoma

Frontiers of Medicine 2023, Volume 17, Issue 2,   Pages 275-289 doi: 10.1007/s11684-022-0945-y

Abstract: The abnormal activation of HER family kinase activity is closely related to the development of human malignancies. In this study, we used HER kinases as targets for the treatment of nasopharyngeal carcinoma (NPC) and explored the anti-tumor effects of the novel pan-HER inhibitor HM781-36B, alone or in combination with cisplatin. We found that HER family proteins were positively expressed in tumor tissues of some NPC patients, and the high levels of those proteins were significantly related to poor prognosis. HM781-36B inhibited NPC in vitro and in vivo. HM781-36B exerted synergistic effects with cisplatin on inhibiting proliferation and promoting apoptosis of NPC cells. In NPC xenograft models in nude mice, HM781-36B and cisplatin synergistically inhibited tumor growth. Downregulating the activity of HER family proteins and their downstream signaling pathways and regulating tumor microenvironment may explain the synergistic anti-tumor effects of HM781-36B and cisplatin. In conclusion, our study provides evidence for HER family proteins as prognostic biomarkers and potential therapeutic targets for NPC. The pan-HER inhibitor HM781-36B alone or in combination with cisplatin represents promising therapeutic effects for the treatment of NPC patients, which provides a new idea for the comprehensive treatment of NPC.

Keywords： epidermal growth factor receptor     ErbB receptors     HM781-36B     nasopharyngeal carcinoma     molecular targetedtherapy     cisplatin    

HTML PDF Collect

Progress in systemic therapy for triple-negative breast cancer

Hongnan Mo, Binghe Xu

Frontiers of Medicine 2021, Volume 15, Issue 1,   Pages 1-10 doi: 10.1007/s11684-020-0741-5

Abstract: treatment strategies, including modified chemotherapy approaches, immune checkpoint inhibitors, and targeted

Keywords： triple-negative breast cancer     immunotherapy     targeted therapy    

HTML PDF Collect

Influence of Survivin-targeted siRNA on the biological features of colorectal carcinoma cells

XIONG Ying, GUO Wen, LI Ting, LI Ke

Frontiers of Medicine 2007, Volume 1, Issue 3,   Pages 304-307 doi: 10.1007/s11684-007-0058-7

Abstract: The transient transfection of survivin-targeted siRNA to Lovo cells and its influence on the biologicalTwo pairs of 19 base pairs (bp) siRNA-specific targeted survivin gene were designed and synthesized byAfter transient transfection of the two survivin-targeted siRNAs to Lovo cells by Lipofectamine™ 2000Based on the results, we can draw a conclusion that the two survivin-targeted siRNAs successfully suppressedIt provides a powerful evidence for colorectal carcinoma gene therapy.

Keywords： control     therapy     influence     Survivin-1     colorectal carcinoma    

HTML PDF Collect

Inhibition of FLT3: A Prototype for Molecular Targeted Therapy in Acute Myeloid Leukemia Review

Meira Yisraeli Salman, Jacob M. Rowe, Nir Weigert

Engineering 2021, Volume 7, Issue 10,   Pages 1354-1368 doi: 10.1016/j.eng.2021.05.020

Abstract:

Modern therapy of acute myeloid leukemia (AML) began in 1973 with the first report of the successfulof these advances have promoted the concept of personalized medicine, which has led to the advent of targetedSuch targeted agents have now become a cornerstone in the management of AML, increasing efficacy andThe focus of this review is on one of the most well-studied targeted agents in AML: the FMS-like tyrosinereview selectively discusses the FLT3 inhibitors in detail, as a model for the other burgeoning targeted

Keywords： AMLTargeted therapy     FLT3 inhibitors     Midostaurin     Gilteritinib     Quizartinib     Sorafenib    

HTML PDF Collect

Title Author Date Type Operation

Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis

Yue Yu, Jie He

Journal Article

Molecular classification and molecular targeted therapy of cancer

Miao Xu, Jianyong Shao, Yixin Zeng

Journal Article

Molecular markers and pathogenically targeted therapy in non-small cell lung cancer

Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD

Journal Article

Molecular targeted therapy of gynecological malignant tumors: the development and challenge, from laboratory

Pengming SUN PhD, MD , Jalid SEHOULI PhD, MD , Lihui WEI BM ,

Journal Article

Synthesis and application of superparamagnetic iron oxide nanoparticles in targeted therapy and imaging

Liangqian Tong, Ming Zhao, Shu Zhu, Jing Chen

Journal Article

Precision medicine in acute lymphoblastic leukemia

Ching-Hon Pui

Journal Article

Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies

Peter B. Alexander,Xiao-Fan Wang

Journal Article

mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?

Shi-Yong Sun

Journal Article

Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects

Zhen Wang, Jianhui Wu, Xiuyun Tian, Chunyi Hao

Journal Article

Progress and challenges in RET-targeted cancer therapy

Journal Article

Potential unreliability of ALK variant allele frequency in the efficacy prediction of targeted therapy

Journal Article

A small-molecule pan-HER inhibitor alone or in combination with cisplatin exerts efficacy against nasopharyngeal carcinoma

Journal Article

Progress in systemic therapy for triple-negative breast cancer

Hongnan Mo, Binghe Xu

Journal Article

Influence of Survivin-targeted siRNA on the biological features of colorectal carcinoma cells

XIONG Ying, GUO Wen, LI Ting, LI Ke

Journal Article

Inhibition of FLT3: A Prototype for Molecular Targeted Therapy in Acute Myeloid Leukemia

Meira Yisraeli Salman, Jacob M. Rowe, Nir Weigert

Journal Article